We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+9.81%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$79.2B
AUM Growth
+$3.07B
(+4%)
Cap. Flow
-$2.3B
Cap. Flow
% of AUM
-2.9%
Top 10 Holdings %
Top 10 Hldgs %
48.93%
Holding
809
New
117
Increased
205
Reduced
335
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$331M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$327M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$319M |
| 4 |
Allison Transmission
ALSN
|
+$195M |
| 5 |
BA.PRA
Boeing Co 6.00% Series A Preferred Stock
BA.PRA
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$853M |
| 2 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$294M |
| 3 |
NVIDIA
NVDA
|
+$266M |
| 4 |
Netflix
NFLX
|
+$190M |
| 5 |
Meta Platforms (Facebook)
META
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.48% |
| 2 | Consumer Discretionary | 18.83% |
| 3 | Communication Services | 18.1% |
| 4 | Healthcare | 11.79% |
| 5 | Financials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FITB
626
Fifth Third Bancorp
FITB
$51.7B
| $44K | ﹤0.01% |
+1,046
| New | +$46.9K |
|
627
monday.com
MNDY
$3.6B
| $44K | ﹤0.01% |
+186
| New | +$51.5K |
|
628
National Health Investors
NHI
$3.61B
| $44K | ﹤0.01% |
639
+189
| +42% | +$14.4K |
|
629
Sportradar
SRAD
$3.89B
| $43K | ﹤0.01% |
+2,485
| New | +$37.5K |
|
630
Target
TGT
$67.6B
| $42K | ﹤0.01% |
308
-270
| -47% | -$38.7K |
|
|
CSR
631
Centerspace
CSR
$935M
| $41K | ﹤0.01% |
614
| – | – |
|
632
CVS Health
CVS
$122B
| $38K | ﹤0.01% |
852
-1,350
| -61% | -$75.7K |
|
633
Leonardo DRS
DRS
$12B
| $37K | ﹤0.01% |
1,145
-34,744
| -97% | -$1.13M |
|
|
PLYM
634
DELISTED
Plymouth Industrial REIT
PLYM
| $36K | ﹤0.01% |
2,003
| – | – |
|
635
Atour Lifestyle Holdings
ATAT
$4.83B
| $28K | ﹤0.01% |
1,054
-268
| -20% | -$7.2K |
|
636
Phillips Edison & Co
PECO
$5.17B
| $22K | ﹤0.01% |
+584
| New | +$22.2K |
|
637
Healthpeak Properties
DOC
$14.5B
| $20K | ﹤0.01% |
966
-2,087
| -68% | -$45.2K |
|
|
NXDT
638
NexPoint Diversified Real Estate Trust
NXDT
$232M
| $19K | ﹤0.01% |
+3,195
| New | +$18.7K |
|
639
General Dynamics
GD
$107B
| $17K | ﹤0.01% |
65
-125
| -66% | -$36K |
|
640
Empire State Realty Trust
ESRT
$812M
| $16K | ﹤0.01% |
1,586
-2,884
| -65% | -$31.3K |
|
641
Public Service Enterprise Group
PEG
$37B
| $16K | ﹤0.01% |
191
-679
| -78% | -$60.1K |
|
|
QXO
642
QXO Inc
QXO
$16.9B
| $16K | ﹤0.01% |
+975
| New | +$15.4K |
|
643
Coca-Cola Europacific Partners
CCEP
$46.9B
| $15K | ﹤0.01% |
+200
| New | +$15.4K |
|
644
Hershey
HSY
$36.4B
| $15K | ﹤0.01% |
86
-240
| -74% | -$43K |
|
645
Xcel Energy
XEL
$48B
| $15K | ﹤0.01% |
+228
| New | +$15.3K |
|
646
Conagra Brands
CAG
$7.14B
| $14K | ﹤0.01% |
+496
| New | +$14.1K |
|
|
HUYA
647
Huya Inc
HUYA
$556M
| $14K | ﹤0.01% |
4,516
| – | – |
|
648
Kraft Heinz
KHC
$29.8B
| $14K | ﹤0.01% |
469
+11
| +2% | +$360 |
|
649
Rithm Capital
RITM
$5.6B
| $12K | ﹤0.01% |
+1,112
| New | +$12K |
|
650
Western Union
WU
$2.16B
| $12K | ﹤0.01% |
+1,121
| New | +$12.4K |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q4 2024 Portfolio in Review
As of Q4 2024, Loomis, Sayles & Company held 809 positions worth $79.2B, up 4% from $76.2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Loomis, Sayles & Company's Q4 2024 filing shows 117 new, 205 increased, 335 reduced and 91 closed positions. Its largest new stake was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M. The largest sale was Tesla, an estimated $853M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q4 2024 buy was Boeing Co 6.00% Series A Preferred Stock: 886,790 shares worth $157M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $331M increase.
- Loomis, Sayles & Company's biggest Q4 2024 reduction was Tesla, cutting an estimated $853M.
- Loomis, Sayles & Company fully exited Medpace in Q4 2024, selling an estimated $68.7M.
- Loomis, Sayles & Company's ten largest holdings make up 49% of its $79.2B portfolio in Q4 2024.
- Loomis, Sayles & Company opened 117 new positions and closed 91 in Q4 2024.
- Loomis, Sayles & Company's portfolio value rose 4% quarter-over-quarter to $79.2B.
Based on Loomis, Sayles & Company's 13F filing for Q4 2024, filed 12 Feb 2025.